Literature DB >> 9738983

Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro.

Y Shi1, S Inoue, R Shinozaki, K Fukue, T Kougo.   

Abstract

Endothelial cells (EC) produce cytokines, such as interleukin (IL)-1, IL-6, IL-8 and granulocyte-macrophage colony-stimulating factor (GM-CSF). These cytokines have an important role in the proliferation and differentiation of hematopoietic progenitor cells. On the other hand, anticancer agents generally cause hematopoietic disorders. However, little is known about the effects of chemotherapeutic agents on the secretion of cytokines from EC. Therefore, we investigated if treatment with platinum compounds may stimulate EC to secrete cytokines. EC newly isolated from a human umbilical vein were exposed to cisplatin, carboplatin, or TRK-710 for 80 min, then the cells were washed and placed in fresh medium. The levels of cytokines in the fresh medium were measured by the ELISA method, the levels of intracellular hydrogen peroxide (H2O2) were measured by flow cytometry, and the rhodamine 123-stained live mitochondria of the EC were observed under a confocal laser microscope. Platinum compounds induced cytokine production in human EC: cisplatin most prominently induced the release of IL-1 and IL-6, and TRK-710 had the greatest ability to induce the release of GM-CSF. Intracellular H2O2 production and IL-8 release were transiently induced immediately after treatment with platinum compounds, leading to IL-1 release when H2O2 production was eliminated. These results may provide new insights into the hematological toxicity induced by anticancer agents and the role of IL-1 and IL-6 secreted from EC in this toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738983      PMCID: PMC5921881          DOI: 10.1111/j.1349-7006.1998.tb03281.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  43 in total

1.  IL-1 stimulates IL-6 production in endothelial cells.

Authors:  M Sironi; F Breviario; P Proserpio; A Biondi; A Vecchi; J Van Damme; E Dejana; A Mantovani
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

2.  Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity.

Authors:  S G Emerson; C A Sieff; E A Wang; G G Wong; S C Clark; D G Nathan
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

3.  Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells.

Authors:  M Yoshizumi; H Kurihara; T Morita; T Yamashita; Y Oh-hashi; T Sugiyama; F Takaku; M Yanagisawa; T Masaki; Y Yazaki
Journal:  Biochem Biophys Res Commun       Date:  1990-01-15       Impact factor: 3.575

4.  Control of granulopoiesis in man.III. inhibition of colony formation by dense leukocytes.

Authors:  F L Baker; H E Broxmeyer; P R Galbraith
Journal:  J Cell Physiol       Date:  1975-10       Impact factor: 6.384

Review 5.  Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

Authors:  M Baggiolini; A Walz; S L Kunkel
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

6.  Human endothelium in cell culture.

Authors:  D G Fryer; G Birnbaum; C N Luttrell
Journal:  J Atheroscler Res       Date:  1966 Mar-Apr

7.  Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator.

Authors:  R H Weisbart; D W Golde; S C Clark; G G Wong; J C Gasson
Journal:  Nature       Date:  1985 Mar 28-Apr 3       Impact factor: 49.962

8.  Cell turnover of capillaries.

Authors:  R L Engerman; D Pfaffenbach; M D Davis
Journal:  Lab Invest       Date:  1967-12       Impact factor: 5.662

9.  Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.

Authors:  P L Triozzi; J A Kim; E W Martin; D C Young; T Benzies; P M Villasmil
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

10.  In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes.

Authors:  I Colditz; R Zwahlen; B Dewald; M Baggiolini
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

View more
  7 in total

1.  Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

Authors:  Mohammad Abu Zaid; Wambui G Gathirua-Mwangi; Chunkit Fung; Patrick O Monahan; Omar El-Charif; Annalynn M Williams; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Ryan Cook; Sandra K Althouse; Shirin Ardeshir-Rouhani-Fard; Paul C Dinh; Howard D Sesso; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis
Journal:  J Natl Compr Canc Netw       Date:  2018-03       Impact factor: 11.908

Review 2.  Biomarkers Predictive of Metabolic Syndrome and Cardiovascular Disease in Childhood Cancer Survivors.

Authors:  Alberto Romano; Ester Del Vescovo; Serena Rivetti; Silvia Triarico; Giorgio Attinà; Stefano Mastrangelo; Palma Maurizi; Antonio Ruggiero
Journal:  J Pers Med       Date:  2022-05-27

3.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10

4.  Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.

Authors:  Renske Altena; Rudolf S N Fehrmann; Hink Boer; Elisabeth G E de Vries; Coby Meijer; Jourik A Gietema
Journal:  PLoS One       Date:  2015-01-15       Impact factor: 3.240

5.  Gastric myoelectric activity during cisplatin-induced acute and delayed emesis reveals a temporal impairment of slow waves in ferrets: effects not reversed by the GLP-1 receptor antagonist, exendin (9-39).

Authors:  Zengbing Lu; Man P Ngan; Ge Lin; David T W Yew; Xiaodan Fan; Paul L R Andrews; John A Rudd
Journal:  Oncotarget       Date:  2017-10-16

Review 6.  Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.

Authors:  Chunkit Fung; Paul Dinh; Shirin Ardeshir-Rouhani-Fard; Kerry Schaffer; Sophie D Fossa; Lois B Travis
Journal:  Adv Urol       Date:  2018-02-18

7.  Changes in hemodynamics, renal blood flow and urine output during continuous renal replacement therapies.

Authors:  S N Fernández; M J Santiago; R González; J López; M J Solana; J Urbano; J López-Herce
Journal:  Sci Rep       Date:  2020-11-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.